Macrogenics (MGNX) Other Non Operating Income (2012 - 2026)
Macrogenics (MGNX) posted quarterly Other Non Operating Income of $1.6 million for Q1 2026, down 7.44% year-over-year from $1.7 million in Q1 2025, and up 8.14% quarter-over-quarter from $1.4 million in Q4 2025.
Macrogenics (MGNX) Other Non Operating Income (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Other Non Operating Income for 15 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 7.44% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $5.9 million (down 29.42% YoY), while the FY2025 annual figure was $6.1 million, down 35.71% from the prior year.
- Other Non Operating Income advanced to $1.6 million in Q1 2026 per MGNX's latest filing, from $1.4 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $50.0 million in Q3 2023 and bottomed at -$841000.0 in Q4 2022.
- Historically, Other Non Operating Income has averaged $4.6 million across 5 years, with a median of $1.6 million in 2025.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 35111.27% — and 2024, when it slumped 95.76%.
- Macrogenics' Other Non Operating Income stood at -$841000.0 in 2022, then soared by 490.25% to $3.3 million in 2023, then slumped by 36.44% to $2.1 million in 2024, then slumped by 31.11% to $1.4 million in 2025, then gained by 8.14% to $1.6 million in 2026.
- Business Quant data shows MGNX's Other Non Operating Income at $1.6 million in Q1 2026, $1.4 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.55 Mn |
| Dec 31, 2025 | 1.44 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.68 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | 2.12 Mn |
| Jun 30, 2024 | 2.52 Mn |
| Mar 31, 2024 | 2.69 Mn |
| Dec 31, 2023 | 3.28 Mn |
| Sep 30, 2023 | 50.00 Mn |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 1.07 Mn |
| Dec 31, 2022 | -841,000.00 |
| Sep 30, 2022 | 142,000.00 |
| Mar 31, 2022 | 195,000.00 |
| Dec 31, 2021 | -466,000.00 |
| Sep 30, 2021 | 101,000.00 |
| Jun 30, 2021 | 344,000.00 |
| Mar 31, 2021 | 21,000.00 |